Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 25 May 2018

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Monitoring intestinal inflammation using fecal calprotectin

Calprotectin could be suitable as a marker for assessing and monitoring disease activity in inflammatory bowel disease, as well as in screening for carcinoma and bowel disease in the general population, finds a study in the European Journal of Gastroenterology and Hepatology.

News image

fiogf49gjkf04

Calprotectin is a neutrophil granulocyte-derived protein that has been found in increased levels in plasma, cerebrospinal fluid, synovial fluid, saliva and urine following infection, inflammation and malignant disease in relevant organs, following activation of monocytes and neutrophil granulocytes.

The protein is also excreted in feces, in which it remains very stable, and so fecal calprotectin concentrations may provide an easy test for assessing infection, disease or inflammatory activity in the alimentary tract.

Calprotectin is known to be an inhibitor of zinc-dependent enzymes that, by competing for zinc, can kill microbes and induce apoptosis in both normal and malignant cells.

Zinc-dependent metalloproteinases are needed for activation of cytokines like tumor necrosis factor alpha and for invasive growth of tumors and so it is thought that calprotectin may therefore participate in the regulation of inflammatory processes and inhibit cancer cell proliferation.

However, it is possible that elevated concentrations of this protein may also induce cell and tissue damage.

It is known that there is accumulation of neutrophils at sites of active inflammatory bowel disease (IBD), leading to the possibility that cytotoxic levels of calprotectin may be reached locally and that this protein may also play an active role in IBD, in addition to being a useful fecal marker.

Therefore, researchers from the departments of Gastroenterology and Clinical Biochemistry at the North Manchester General Hospital in Manchester, England, have assessed the potential of measuring calprotectin in feces as a method of screening for alimentary inflammation and neoplasia.

Consented patients attending for routine endoscopy were requested to provide feces.

Of the initial 30 patients enrolled, 17 provided feces before and 1 week after endoscopy.

A further 116 patients with planned endoscopy provided feces prior to undergoing endoscopy.

The group comprised 43 patients with upper gastrointestinal lesions, 7 patients with IBD, a further 7 patients with irritable bowel disease, 31 patients with colonic disorders, and 28 normal people.

A final 18 patients with known inflammatory bowel disease (7 patients), gastric carcinoma (1 patient), colorectal cancer (8 patients) and colorectal adenoma (2 patients) also had stool samples analyzed.

Fecal calprotectin:
Elevated in inflammation and cancer
European Journal of Gastroenterology & Hepatology

Feces were analyzed using enzyme-linked immunosorbent assay (ELISA) techniques.

Following such analysis, no definite differences between pre- and post-endoscopy calprotectin were found.

Analyses of samples from subsequent patients were therefore carried out on pre-endoscopy feces only, as this was considered preferable.

Upper-gastrointestinal disorders showed little difference in calprotectin levels: Barrett's esophagus (median 6.8 mg/l), gastric ulcer (median 6.5 mg/l) or gastritis/duodenitis (median 5.2 mg/l).

However, these were all higher than the median calprotectin level of normal subjects (4.5 mg/l).

The esophageal and gastric carcinoma median was elevated significantly at 30 mg/l, while inflammatory bowel disease was also associated with marked elevation (Crohn's disease, 31.2 mg/l; ulcerative colitis, 116.2 mg/l).

Colorectal polyps (median 3.7 mg/l) and adenoma (median 3.8 mg/l) showed no elevated levels in contrast to colorectal carcinoma (median 53.4 mg/l).

The elevated calprotectin in IBD and colorectal carcinoma combined gave a sensitivity of 81.8% and a specificity of 73.2%.

"Calprotectin levels are elevated in inflammation and cancer but are not helpful in differentiating between these disorders," commented Dr Christopher B. Summerton, one of the study authors, adding, "In our series, calprotectin was not elevated in colonic polyps or adenomata."

"However," he continued, "Calprotectin could be helpful as a screening method in a general gastroenterology population for inflammatory bowel disease and those with carcinoma, as well as assessing and monitoring disease activity in inflammatory bowel disease."

Eur J Gastroenterol Hepatol 2002; 14(8): 841-845
06 August 2002

Go to top of page Email this page Email this page to a colleague

 25 May 2018 
Colorectal cancer–specific mortality
 25 May 2018 
Technology to increase colorectal cancer screening
 25 May 2018 
Post‐operative complications in elderly IBD
 24 May 2018 
Patient-reported outcome measures in IBD trials
 24 May 2018 
Alcohol consumption and outcomes in drug-induced liver injury
 24 May 2018 
Precision medicine for tumors
 23 May 2018 
Management of perianal fistulas in Crohn’s disease
 23 May 2018 
Cardiovascular risk in diabetes mellitus with NAFLD
 23 May 2018 
High body mass index is and ulcerative colitis
 22 May 2018 
Worldwide H.pylori prevalence
 22 May 2018 
PPI and risk of stroke
 22 May 2018 
Online tool predicts bowel dysfunction severity prior to anterior resection
 21 May 2018 
Depressive symptoms in IBD youth
 21 May 2018 
PPI use and cognitive decline
 21 May 2018 
Fecal incontinence and quality of life in IBD
 18 May 2018 
Esophageal dilatation in clinical practice 
 17 May 2018 
IBD and later extraintestinal manifestations
 17 May 2018 
Repeat stool DNA testing
 17 May 2018 
IBS and chronic fatigue following GI infection
 16 May 2018 
Factors associated with fecal incontinence
 16 May 2018 
Diagnostic delay in Crohn's disease
 16 May 2018 
Cardiovascular risk in diabetes mellitus with NAFLD
 15 May 2018 
Guidelines for management of Crohn's
 15 May 2018 
Hep B in the Grey Zone
 15 May 2018 
New therapies for CDI
 14 May 2018 
Blood test for the diagnosis of fibrotic NASH
 14 May 2018 
Outcomes at bariatric centers of excellence
 14 May 2018 
Management of perianal fistulas in Crohn’s
 11 May 2018 
Detection of undiagnosed celiac disease
 11 May 2018 
Alcohol consumption and drug-induced liver injury
 10 May 2018 
Colorectal cancer screening
 10 May 2018 
Fibrosis in patients with chronic hepatitis B
 09 May 2018 
Fecal incontinence
 09 May 2018 
Health problems and IBS
 09 May 2018 
Esophageal dilatation in clinical practice 
 07 May 2018 
Omitting antibiotics in uncomplicated acute diverticulitis
 07 May 2018 
Health problems and IBS
 07 May 2018 
Assessment of diminutive colorectal polyps
 04 May 2018 
National Institutes of Health workshop and obesity
 04 May 2018 
Factors associated with fecal incontinence
 04 May 2018 
Colorectal cancer screening and ethnic inequities
 03 May 2018 
Gastrointestinal ultrasound in IBD
 03 May 2018 
Ultransonography in postsurgical recurrence in Crohn's
 02 May 2018 
Symptom assessment in cirrhotic ascites
 02 May 2018 
Hep C antiviral treatment and liver cancer risk
 02 May 2018 
Chronic Hep B
 01 May 2018 
European guidelines on pancreatic cystic neoplasms
 01 May 2018 
Interferon‐free regimens in Hep C
 01 May 2018 
Age at IBD onset and extraintestinal complications
 30 April 2018 
Formula for preterm infants
 30 April 2018 
Primary antibiotic resistance and sequential therapy for H. pylori
 27 April 2018 
Eastern and western practices for endoscopic resection of colorectal lesions
 27 April 2018 
Anxiety scale for chronic esophageal disease
 27 April 2018 
Disease activity in eosinophilic esophagitis
 26 April 2018 
Obesity and physical activity in diverticulosis
 26 April 2018 
Primary sclerosing cholangitis in the USA
 25 April 2018 
Aspirin and pancreatic cancer
 25 April 2018 
Central mediators of irinotecan-induced steatohepatitis
 25 April 2018 
Neuroimaging in Hep C
 24 April 2018 
Scoring system identifies cancer risk in Barrett's

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2018 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us